Biofrontera INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BFRI
Biofrontera INCBiofrontera Inc. files an amendment to its 2025 annual report on Form 10-K/A, primarily to include an exhibit and new certifications.
NASDAQ
BFRI
Biofrontera INCBiofrontera Inc. reported an 11.8% revenue increase and reduced net loss in 2025, driven by a strategic acquisition and cost efficiencies, despite facing substantial doubt about its ability to continue as a going concern.
NASDAQ
BFRI
Biofrontera INC10-K: Biofrontera Inc. Reports Increased Revenue but Continues to Face Going Concern Challenges in 2024
Biofrontera Inc. reports a revenue increase in 2024 driven by Ameluz sales and the launch of RhodoLED XL, but acknowledges substantial doubt about its ability to continue as a going concern.
NASDAQ
BFRI
Biofrontera INCBiofrontera Inc.'s 10-K filing details the terms of its common stock, warrants, and stockholder rights plan, including voting rights, dividend entitlements, and anti-takeover provisions.